NASDAQ:HRTX Heron Therapeutics (HRTX) Stock Price, News & Analysis $1.91 +0.01 (+0.53%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.91 0.00 (0.00%) As of 07/25/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Heron Therapeutics Stock (NASDAQ:HRTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Heron Therapeutics alerts:Sign Up Key Stats Today's Range$1.90▼$1.9250-Day Range$1.83▼$2.2352-Week Range$1.04▼$3.16Volume589,813 shsAverage Volume1.33 million shsMarket Capitalization$291.39 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company Overview Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Read More Heron Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreHRTX MarketRank™: Heron Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 264th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHeron Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Heron Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($0.13) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -31.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -31.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Heron Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.71% of the float of Heron Therapeutics has been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 23.4, which indicates bearish sentiment.Change versus previous monthShort interest in Heron Therapeutics has recently increased by 7.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.96 Percentage of Shares Shorted25.71% of the float of Heron Therapeutics has been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 23.4, which indicates bearish sentiment.Change versus previous monthShort interest in Heron Therapeutics has recently increased by 7.92%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment1.43 News SentimentHeron Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Heron Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for HRTX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.86% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Heron Therapeutics' insider trading history. Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTX Stock News HeadlinesHeron Therapeutics: Middling Performance From Approved Therapies With No PipelineJuly 22, 2025 | seekingalpha.comHRTX Heron Therapeutics, Inc. - Seeking AlphaJuly 10, 2025 | seekingalpha.comElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by 2025, robots will shift from novelty to necessity — disrupting nearly every industry in their path. But one overlooked sector could become the real winner… and one little-known company may be the best way to get ahead of the boom.July 26 at 2:00 AM | Weiss Ratings (Ad)With 60% institutional ownership, Heron Therapeutics, Inc. (NASDAQ:HRTX) is a favorite amongst the big gunsJuly 1, 2025 | finance.yahoo.comHC Wainwright & Co. Initiates Coverage of Heron Therapeutics (HRTX) with Buy RecommendationJune 11, 2025 | msn.comResults: Heron Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 9, 2025 | finance.yahoo.comEarnings call transcript: Heron Therapeutics beats Q1 2025 expectations, stock surgesMay 7, 2025 | investing.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Call TranscriptMay 7, 2025 | insidermonkey.comSee More Headlines HRTX Stock Analysis - Frequently Asked Questions How have HRTX shares performed this year? Heron Therapeutics' stock was trading at $1.53 at the start of the year. Since then, HRTX shares have increased by 24.8% and is now trading at $1.91. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) posted its quarterly earnings results on Tuesday, May, 6th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The biotechnology company had revenue of $38.90 million for the quarter, compared to the consensus estimate of $37.08 million. Read the conference call transcript. Does Heron Therapeutics have any subsidiaries? The following companies are subsidiaries of Heron Therapeutics: Heron Therapeutics B.V.. Who are Heron Therapeutics' major shareholders? Top institutional investors of Heron Therapeutics include Congress Park Capital LLC (1.49%), Cyndeo Wealth Partners LLC (0.16%) and Palumbo Wealth Management LLC (0.09%). Insiders that own company stock include Adam Morgan, Craig A Collard, Ira Duarte and William P Forbes. View institutional ownership trends. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings5/06/2025Today7/25/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRTX CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees300Year Founded1983Price Target and Rating Average Price Target for Heron Therapeutics$5.00 High Price Target$6.00 Low Price Target$4.00 Potential Upside/Downside+161.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.58 million Net Margins-5.24% Pretax Margin-5.24% Return on EquityN/A Return on Assets-3.43% Debt Debt-to-Equity RatioN/A Current Ratio2.40 Quick Ratio1.76 Sales & Book Value Annual Sales$144.29 million Price / Sales2.02 Cash FlowN/A Price / Cash FlowN/A Book Value($0.22) per share Price / Book-8.68Miscellaneous Outstanding Shares152,560,000Free Float143,624,000Market Cap$291.39 million OptionableOptionable Beta1.18 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:HRTX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.